Effect of non-synonymous single-nucleotide polymorphism of human carboxyl esterase


  • GOUTHAM YERRAKULA Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
  • SAMUEL GIDEON GEORGE Department of Pharmacy Practice, Krupanidhi College of Pharmacy, Bangalore
  • KRISHNA KUMAR D Department of Pharmacy Practice, The Erode College of Pharmacy & Research Institute, Erode
  • ANAND VIJAYA KUMAR PR Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
  • JAWAHAR N Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
  • SENTHIL VENKATACHALAM Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India https://orcid.org/0000-0003-3110-1229




carboxylesterase 1, Dabigatran, polymorphism


Objective: Dabigatran Etexilate is an oral acting direct thrombin inhibitor used for prophylaxis of cardio embolic events in non-valvular atrial fibrillation patients. Genetic polymorphisms in hCES1 gene can significantly alter the conformations of the enzyme drug binding and impair the catalytic ability. Hence this study is performed to determine the effect of single nucleotide variations on dabigatran activation by hCES1.

Methods: Energy minimization was performing using YASARA server. Dihedral angles of the modeled targets were visualized using Ramachandran Plot. We performed molecular docking analysis with Autodock 4.2. Three dimensional grid was constructed using Autogrid. Docked complexes were visualized using Pymol Viewer.

Results: Significant differences in the binding energy and conformations of Dabigatran in the active site of the target was observed between the Ser75Asn, Ala158Val, Asp203Glu, Ala269Ser and Thr290Met variants. The catalytic triad was completely or partially disrupted in the variants suggestive of altered enzyme activity.

Co­nclusion: The binding energy of Dabigatran with the mutant (79Ala, 221Ala, 354Ala and 468Ala) was found to be less than that of the wild type. This indicates that the presence of functional non synonymous polymorphism in the hCES1 significantly alters the binding of Dabigatran. Hence patients who have this SNP (332G>A, 581C>T, 717C>A, 913C>T, 977C>T) would have decreased hCES1 function which would result in therapeutic failure or sub therapeutic drug action.


Download data is not yet available.


Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131-6.

Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. Journal of the American Heart Association. 2016;5(6):e003725.

Gouin‐Thibault I, Delavenne X, Blanchard A, Siguret V, Salem J, Narjoz C, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB 1 genetic polymorphisms and interaction with clarithromycin. Journal of Thrombosis and Haemostasis. 2017;15(2):273-83.

Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clinical and Applied Thrombosis/Hemostasis. 2009;15(1_suppl):9S-16S.

Laizure SC, Parker RB, Herring VL, Hu Z-Y. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metabolism and Disposition. 2014;42(2):201-6.

Shi J, Wang X, Nguyen J-H, Bleske BE, Liang Y, Liu L, et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochemical pharmacology. 2016;119:76-84.

Zhu H-J, Patrick KS, Yuan H-J, Wang J-S, Donovan JL, DeVane CL, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. The American Journal of Human Genetics. 2008;82(6):1241-8.

Nelveg-Kristensen KE, Bie P, Ferrero L, Bjerre D, Bruun NE, Egfjord M, et al. Pharmacodynamic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors. Plos one. 2016;11(9):e0163341.

Wang X, Wang G, Shi J, Aa J, Comas R, Liang Y, et al. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors. The pharmacogenomics journal. 2016;16(3):220-30.

Bjerre D, Berg Rasmussen H, INDICES Consortium T. Novel approach for CES1 genotyping: integrating single nucleotide variants and structural variation. Pharmacogenomics. 2018;19(4):349-59.

Suzaki Y, Uemura N, Takada M, Ohyama T, Itohda A, Morimoto T, et al. The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans. European journal of clinical pharmacology. 2013;69(1):21-30.

Kaur, K., Kaur, P., Mittal, A., Nayak, S. K., & Khatik, G. L. (2017). Design and molecular docking studies of novel antimicrobial peptides using autodock molecular docking software. Asian Journal of Pharmaceutical and Clinical Research, 28-31.

Sultana MN, Qureshi SY, Fatima I, Jabeen W, Obaid M. A prospective observational study on the assessment of potential drug-drug interactions and management of post-complications in stroke patients at a tertiary care teaching hospital. Int j pharm pharm sci. 2021 nov;13(11):8-14.

Sharma A, Kunwar S, Vaishali, Agarwal V, Singh C, Sharma MD, Chauhan N. Molecular docking: an explanatory approach in structure-based drug designing and discovery. Int j pharm pharm sci. 2021 jun;13(6):6-12.

Vene N, Mavri A, Gubenšek M, Tratar G, Vižintin Cuderman T, Pohar Perme M, et al. Risk of thromboembolic events in patients with non-valvular atrial fibrillation after dabigatran or rivaroxaban discontinuation–data from the ljubljana registry. PLoS One. 2016;11(6):e0156943.

Wang D, Zou L, Jin Q, Hou J, Ge G, Yang L. Human carboxylesterases: a comprehensive review. Acta Pharmaceutica Sinica B. 2018;8(5):699-712.

Bencharit S, Morton CL, Hyatt JL, Kuhn P, Danks MK, Potter PM, et al. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chemistry & biology. 2003;10(4):341-9.

Vistoli G, Pedretti A, Mazzolari A, Testa B. Homology modeling and metabolism prediction of human carboxylesterase-2 using docking analyses by GriDock: a parallelized tool based on AutoDock 4.0. Journal of computer-aided molecular design. 2010;24(9):771-87.

Jendele L, Krivak R, Skoda P, Novotny M, Hoksza D. PrankWeb: a web server for ligand binding site prediction and visualization. Nucleic acids research. 2019;47(W1):W345-W9.

Krieger E, Koraimann G, Vriend G. Increasing the precision of comparative models with YASARA NOVA—a self‐parameterizing force field. Proteins: Structure, Function, and Bioinformatics. 2002;47(3):393-402.

Nzabonimpa GS, Rasmussen HB, Brunak S, Taboureau O, Consortium I. Investigating the impact of missense mutations in hCES1 by in silico structure-based approaches. Drug metabolism and personalized therapy. 2016;31(2):97-106.

Wang X, Rida N, Shi J, Wu AH, Bleske BE, Zhu H-J. A comprehensive functional assessment of carboxylesterase 1 nonsynonymous polymorphisms. Drug Metabolism and Disposition. 2017;45(11):1149-55.

Chen F, Zhang B, Parker RB, Laizure SC. Clinical implications of genetic variation in carboxylesterase drug metabolism. Expert opinion on drug metabolism & toxicology. 2018;14(2):131-42.

Her L, Zhu H-J. Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators. Drug Metabolism and Disposition. 2020;48(3):230-44.

Kajy M, Mathew A, Ramappa P. Treatment failures of direct oral anticoagulants. LWW; 2021.



How to Cite

YERRAKULA, G., GEORGE, S. G., D, K. K., PR, A. V. K., N, J., & VENKATACHALAM, S. (2022). EFFECT OF NON-SYNONYMOUS SINGLE-NUCLEOTIDE POLYMORPHISM OF HUMAN CARBOXYL ESTERASE 1 ON THE BIOACTIVATION OF DABIGATRAN ETEXILATE: Effect of non-synonymous single-nucleotide polymorphism of human carboxyl esterase. International Journal of Applied Pharmaceutics, 14(5). https://doi.org/10.22159/ijap.2022v14i5.44682



Original Article(s)